+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Middle East Neurology Clinical Trials Market Size, Share & Trends Analysis Report by Phase (Phase I, Phase II, Phase III, Phase IV), Study Design, Indication, Indication by Study Design, Indication by Phase, Value Chain, and Country with Growth Forecasts, 2025-2033

  • PDF Icon

    Report

  • 120 Pages
  • September 2025
  • Region: Middle East
  • Grand View Research
  • ID: 6176658
REQUEST CUSTOMIZATION
Description Jump to:
The Middle East neurology clinical trials market size was estimated at USD 45.19 Million in 2025 and is projected to reach USD 68.78 million by 2033, growing at a CAGR of 5.39% from 2025 to 2033. The market growth is driven by the increasing burden of neurological diseases, an aging population, and enhanced tertiary care capacity.

Besides, growing regional investments have strengthened efforts to improve the academic medical centers, specialized neuroscience units, and robust IRB/ethics processes, further contributing to market growth. In addition, progress in data interoperability has facilitated feasibility assessments, while sovereign and philanthropic funding has led to new brain health initiatives in the region. Further, deploying improved imaging, EEG, and genomic capabilities and recruiting large patient populations contribute to market growth.

Moreover, growing clinical trial volumes in the region have witnessed rising global-local partnerships, streamlined approvals, and site accreditation programs supporting improved GCP compliance. For instance, currently the regional activity predominantly focuses on Phase II trials for neurodegeneration and pain, and Phase III programs have emerged for conditions like multiple sclerosis, epilepsy, and migraine. Registries for device-assisted stroke and movement disorders are prominent in Phase III/IV. At the same time, preliminary Phase I work for rare neurometabolic and gene-therapy candidates has commenced in the market. In addition, growing adoption of decentralized and hybrid trial models utilizing eConsent, home-based assessments, wearables, and imaging biomarkers has resulted in shorter cycle times and improved retention rates. Increased trial throughput has led to expanded CRO operations, enhanced investigator capacity, and more extensive data assets, thereby speeding up protocol initiation and fostering market growth through higher site utilization and repeat engagement from sponsors.

Furthermore, growing strategic initiatives to establish designated neuroscience centers for developing national biobanks & registries, and creating public-private platforms for sharing imaging & omics data, support market growth. Besides, growing regional expansion through cross-border agreements, consent frameworks, and incentives that connect late-stage trials to local manufacturing, compassionate use, and post-marketing evidence generation are expected to drive the market. Such factors are expected to drive the growth of the Middle East neurology clinical trials industry over the estimated time period.

Middle East Neurology Clinical Trials Market Report Segmentation

This report forecasts revenue growth at the regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the Middle East neurology clinical trials market report based onphase, study design, indication, indication by study design, indication by phase, value chain, and country:

Phase Outlook (Revenue, USD Million, 2021-2033)

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Study Design Outlook (Revenue, USD Million, 2021-2033)

  • Interventional
  • Observational
  • Expanded Access

Indication Outlook (Revenue, USD Million, 2021-2033)

  • Alzheimer’s Disease
  • Depression (MDD)
  • Parkinson's Disease (PD)
  • Epilepsy
  • Stroke
  • Traumatic Brain Injury (TBI)
  • Amyotrophic Lateral Sclerosis (ALS)
  • Huntington's Disease
  • Muscle Regeneration
  • Others

Indication by Study Design Outlook (Revenue, USD Million, 2021-2033)

  • Alzheimer’s Disease
  • Depression (MDD)
  • Parkinson's Disease (PD)
  • Epilepsy
  • Stroke
  • Traumatic Brain Injury (TBI)
  • Amyotrophic Lateral Sclerosis (ALS)
  • Huntington's Disease
  • Muscle Regeneration
  • Others

Indication by Phase Outlook (Revenue, USD Million, 2021-2033)

  • Alzheimer’s Disease
  • Depression (MDD)
  • Parkinson's Disease (PD)
  • Epilepsy
  • Stroke
  • Traumatic Brain Injury (TBI)
  • Amyotrophic Lateral Sclerosis (ALS)
  • Huntington's Disease
  • Muscle Regeneration
  • Others

Value Chain Outlook (Revenue, USD Million, 2021-2033)

  • In-house
  • CROs
  • Investigator Sites/Clinical Sites

Value Chain Outlook (Revenue, USD Million, 2021-2033)

  • Saudi Arabia
  • UAE
  • Kuwait
  • Qatar
  • Oman

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segmental and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve

This product will be delivered within 2 business days.

Table of Contents

Chapter 1. Research Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Study Design
1.2.2. Indication
1.2.3. Indication by Study Design
1.2.4. Indication by Phase
1.2.5. Value Chain
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information Or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.7.2. Parent Market Analysis
1.8. List of Secondary Sources
1.9. List of Abbreviations
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Middle East Neurology Clinical Trials Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing prevalence of neurological diseases such as Alzheimer disease, epilepsy, and stroke
3.2.1.2. Growing adoption of novel technologies in clinical research
3.2.1.3. Rising number of CROs providing Middle East Neurology Clinical research services
3.2.1.4. Increasing funding for neurological studies by public organizations
3.2.2. Market Restraint Analysis
3.2.2.1. Increased associated with Middle East Neurology Clinical studies
3.2.2.2. High failure rate coupled with patient dropout issues associated with neurological clinical trials
3.2.3. Market Challenges
3.2.4. Market Opportunities
3.3. Technology Landscape
3.4. Pricing Model Analysis
3.5. R&D Spending Analysis (2018-2024)
3.6. Clinical Trial Volume Analysis, 2024
3.7. Tariff Impact Analysis
3.8. Value Chain Analysis
3.8.1. Supply Trends
3.8.2. Demand Trends
3.9. Market Analysis Tools
3.9.1. Porter’s Five Force Analysis
3.9.2. PESTEL by SWOT Analysis
3.9.3. COVID-19 Impact Analysis
Chapter 4. Middle East Neurology Clinical Trials Market: Phase Estimates & Trend Analysis
4.1. Middle East Neurology Clinical Trials Market, by Phase: Segment Dashboard
4.2. Middle East Neurology Clinical Trials Market, by Phase: Movement Analysis
4.3. Middle East Neurology Clinical Trials Market Estimates & Forecasts, by Phase, 2021-2033 (USD Million)
4.4. Phase I
4.4.1. Phase I Market Estimates and Forecasts, 2021-2033 (USD Million)
4.5. Phase II
4.5.1. Phase II Market Estimates and Forecasts, 2021-2033 (USD Million)
4.6. Phase III
4.6.1. Phase III Market Estimates and Forecasts, 2021-2033 (USD Million)
4.7. Phase IV
4.7.1. Phase IV Market Estimates and Forecasts, 2021-2033 (USD Million)
Chapter 5. Middle East Neurology Clinical Trials Market: Study Design Estimates & Trend Analysis
5.1. Middle East Neurology Clinical Trials Market, by Study Design: Segment Dashboard
5.2. Middle East Neurology Clinical Trials Market, by Study Design: Movement Analysis
5.3. Middle East Neurology Clinical Trials Market Estimates & Forecasts, by Study Design, 2021-2033 (USD Million)
5.4. Interventional
5.4.1. Interventional Market Estimates and Forecasts, 2021-2033 (USD Million)
5.5. Observational
5.5.1. Observational Market Estimates and Forecasts, 2021-2033 (USD Million)
5.6. Expanded Access
5.6.1. Expanded Access Market Estimates and Forecasts, 2021-2033 (USD Million)
Chapter 6. Middle East Neurology Clinical Trials Market: Indication Estimates & Trend Analysis
6.1. Middle East Neurology Clinical Trials Market, by Indication: Segment Dashboard
6.2. Middle East Neurology Clinical Trials Market, by Indication: Movement Analysis
6.3. Middle East Neurology Clinical Trials Market Estimates & Forecasts, by Indication, 2021-2033 (USD Million)
6.4. Alzheimer’s Disease
6.4.1. Alzheimer’s Disease Market Estimates and Forecasts, 2021-2033 (USD Million)
6.5. Depression (MDD)
6.5.1. Depression (MDD) Market Estimates and Forecasts, 2021-2033 (USD Million)
6.6. Parkinson's Disease (PD)
6.6.1. Parkinson's Disease (PD) Market Estimates and Forecasts, 2021-2033 (USD Million)
6.7. Epilepsy
6.7.1. Epilepsy Market Estimates and Forecasts, 2021-2033 (USD Million)
6.8. Stroke
6.8.1. Stroke Market Estimates and Forecasts, 2021-2033 (USD Million)
6.9. Traumatic Brain Injury (TBI)
6.9.1. Traumatic Brain Injury (TBI) Market Estimates and Forecasts, 2021-2033 (USD Million)
6.10. Amyotrophic Lateral Sclerosis (ALS)
6.10.1. Amyotrophic Lateral Sclerosis (ALS) Market Estimates and Forecasts, 2021-2033 (USD Million)
6.11. Huntington's Disease
6.11.1. Huntington's Disease Market Estimates and Forecasts, 2021-2033 (USD Million)
6.12. Muscle Regeneration
6.12.1. Muscle Regeneration Market Estimates and Forecasts, 2021-2033 (USD Million)
6.13. Others
6.13.1. Others Market Estimates and Forecasts, 2021-2033 (USD Million)
Chapter 7. Middle East Neurology Clinical Trials Market: Indication by Study Design Estimates & Trend Analysis
7.1. Middle East Neurology Clinical Trials Market, Indication by Study Design: Segment Dashboard
7.2. Middle East Neurology Clinical Trials Market, Indication by Study Design: Movement Analysis
7.3. Middle East Neurology Clinical Trials Market Estimates & Forecasts, Indication by Study Design, 2021-2033 (USD Million)
7.4. Alzheimer’s Disease
7.4.1. Alzheimer’s Disease Market Estimates and Forecasts, 2021-2033 (USD Million)
7.4.2. Alzheimer’s Disease Interventional
7.4.2.1. Alzheimer’s Disease Interventional Market Estimates and Forecasts, 2021-2033 (USD Million)
7.4.3. Alzheimer’s Disease Observational
7.4.3.1. Alzheimer’s Disease Observational Market Estimates and Forecasts, 2021-2033 (USD Million)
7.4.4. Alzheimer’s Disease Expanded Access
7.4.4.1. Alzheimer’s Disease Expanded Access Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5. Depression (MDD)
7.5.1. Depression (MDD) Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.2. Depression (MDD) Interventional
7.5.2.1. Depression (MDD) Interventional Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.3. Depression (MDD) Observational
7.5.3.1. Depression (MDD) Observational Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.4. Depression (MDD) Expanded Access
7.5.4.1. Depression (MDD) Expanded Access Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6. Parkinson’s Disease (PD)
7.6.1. Parkinson’s Disease (PD) Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6.2. Parkinson’s Disease (PD) Interventional
7.6.2.1. Parkinson’s Disease (PD) Interventional Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6.3. Parkinson’s Disease (PD) Observational
7.6.3.1. Parkinson’s Disease (PD) Observational Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6.4. Parkinson’s Disease (PD) Expanded Access
7.6.4.1. Parkinson’s Disease (PD) Expanded Access Market Estimates and Forecasts, 2021-2033 (USD Million)
7.7. Epilepsy
7.7.1. Epilepsy Market Estimates and Forecasts, 2021-2033 (USD Million)
7.7.2. Epilepsy Interventional
7.7.2.1. Epilepsy Interventional Market Estimates and Forecasts, 2021-2033 (USD Million)
7.7.3. Epilepsy Observational
7.7.3.1. Epilepsy Observational Market Estimates and Forecasts, 2021-2033 (USD Million)
7.7.4. Epilepsy Expanded Access
7.7.4.1. Epilepsy Expanded Access Market Estimates and Forecasts, 2021-2033 (USD Million)
7.8. Stroke
7.8.1. Stroke Market Estimates and Forecasts, 2021-2033 (USD Million)
7.8.2. Stroke Interventional
7.8.2.1. Stroke Interventional Market Estimates and Forecasts, 2021-2033 (USD Million)
7.8.3. Stroke Observational
7.8.3.1. Stroke Observational Market Estimates and Forecasts, 2021-2033 (USD Million)
7.8.4. Stroke Expanded Access
7.8.4.1. Stroke Expanded Access Market Estimates and Forecasts, 2021-2033 (USD Million)
7.9. Traumatic Brain Injury (TBI)
7.9.1. Traumatic Brain Injury (TBI) Market Estimates and Forecasts, 2021-2033 (USD Million)
7.9.2. Traumatic Brain Injury (TBI) Interventional
7.9.2.1. Traumatic Brain Injury (TBI) Interventional Market Estimates and Forecasts, 2021-2033 (USD Million)
7.9.3. Traumatic Brain Injury (TBI) Observational
7.9.3.1. Traumatic Brain Injury (TBI) Observational Market Estimates and Forecasts, 2021-2033 (USD Million)
7.9.4. Traumatic Brain Injury (TBI) Expanded Access
7.9.4.1. Traumatic Brain Injury (TBI) Expanded Access Market Estimates and Forecasts, 2021-2033 (USD Million)
7.10. Amyotrophic Lateral Sclerosis (ALS)
7.10.1. Amyotrophic Lateral Sclerosis (ALS) Market Estimates and Forecasts, 2021-2033 (USD Million)
7.10.2. Amyotrophic Lateral Sclerosis (ALS) Interventional
7.10.2.1. Amyotrophic Lateral Sclerosis (ALS) Interventional Market Estimates and Forecasts, 2021-2033 (USD Million)
7.10.3. Amyotrophic Lateral Sclerosis (ALS) Observational
7.10.3.1. Amyotrophic Lateral Sclerosis (ALS) Observational Market Estimates and Forecasts, 2021-2033 (USD Million)
7.10.4. Amyotrophic Lateral Sclerosis (ALS) Expanded Access
7.10.4.1. Amyotrophic Lateral Sclerosis (ALS) Expanded Access Market Estimates and Forecasts, 2021-2033 (USD Million)
7.11. Huntington’s Disease
7.11.1. Huntington’s Disease Market Estimates and Forecasts, 2021-2033 (USD Million)
7.11.2. Huntington’s Disease Interventional
7.11.2.1. Huntington’s Disease Interventional Market Estimates and Forecasts, 2021-2033 (USD Million)
7.11.3. Huntington’s Disease Observational
7.11.3.1. Huntington’s Disease Observational Market Estimates and Forecasts, 2021-2033 (USD Million)
7.11.4. Huntington’s Disease Expanded Access
7.11.4.1. Huntington’s Disease Expanded Access Market Estimates and Forecasts, 2021-2033 (USD Million)
7.12. Muscle Regeneration
7.12.1. Muscle Regeneration Market Estimates and Forecasts, 2021-2033 (USD Million)
7.12.2. Muscle Regeneration Interventional
7.12.2.1. Muscle Regeneration Interventional Market Estimates and Forecasts, 2021-2033 (USD Million)
7.12.3. Muscle Regeneration Observational
7.12.3.1. Muscle Regeneration Observational Market Estimates and Forecasts, 2021-2033 (USD Million)
7.12.4. Muscle Regeneration Expanded Access
7.12.4.1. Muscle Regeneration Expanded Access Market Estimates and Forecasts, 2021-2033 (USD Million)
7.13. Others
7.13.1. Others Market Estimates and Forecasts, 2021-2033 (USD Million)
7.13.2. Others Interventional
7.13.2.1. Others Interventional Market Estimates and Forecasts, 2021-2033 (USD Million)
7.13.3. Others Observational
7.13.3.1. Others Observational Market Estimates and Forecasts, 2021-2033 (USD Million)
7.13.4. Others Expanded Access
7.13.4.1. Others Expanded Access Market Estimates and Forecasts, 2021-2033 (USD Million)
Chapter 8. Middle East Neurology Clinical Trials Market: Indication by Phase Estimates & Trend Analysis
8.1. Middle East Neurology Clinical Trials Market, Indication by Phase: Segment Dashboard
8.2. Middle East Neurology Clinical Trials Market, Indication by Phase: Movement Analysis
8.3. Middle East Neurology Clinical Trials Market Estimates & Forecasts, Indication by Phase, 2021-2033 (USD Million)
8.4. Alzheimer’s Disease
8.4.1. Alzheimer’s Disease Market Estimates and Forecasts, 2021-2033 (USD Million)
8.4.2. Alzheimer’s Disease Phase I
8.4.2.1. Alzheimer’s Disease Phase I Market Estimates and Forecasts, 2021-2033 (USD Million)
8.4.3. Alzheimer’s Disease Phase II
8.4.3.1. Alzheimer’s Disease Phase II Market Estimates and Forecasts, 2021-2033 (USD Million)
8.4.4. Alzheimer’s Disease Phase III
8.4.4.1. Alzheimer’s Disease Phase III Market Estimates and Forecasts, 2021-2033 (USD Million)
8.4.5. Alzheimer’s Disease Phase IV
8.4.5.1. Alzheimer’s Disease Phase IV Market Estimates and Forecasts, 2021-2033 (USD Million)
8.5. Depression (MDD)
8.5.1. Depression (MDD) Market Estimates and Forecasts, 2021-2033 (USD Million)
8.5.2. Depression (MDD) Phase I
8.5.2.1. Depression (MDD) Phase I Market Estimates and Forecasts, 2021-2033 (USD Million)
8.5.3. Depression (MDD) Phase II
8.5.3.1. Depression (MDD) Phase II Market Estimates and Forecasts, 2021-2033 (USD Million)
8.5.4. Depression (MDD) Phase III
8.5.4.1. Depression (MDD) Phase III Market Estimates and Forecasts, 2021-2033 (USD Million)
8.5.5. Depression (MDD) Phase IV
8.5.5.1. Depression (MDD) Phase IV Market Estimates and Forecasts, 2021-2033 (USD Million)
8.6. Parkinson's Disease (PD)
8.6.1. Parkinson's Disease (PD) Market Estimates and Forecasts, 2021-2033 (USD Million)
8.6.2. Parkinson's Disease (PD) Phase I
8.6.2.1. Parkinson's Disease (PD) Phase I Market Estimates and Forecasts, 2021-2033 (USD Million)
8.6.3. Parkinson's Disease (PD) Phase II
8.6.3.1. Parkinson's Disease (PD) Phase II Market Estimates and Forecasts, 2021-2033 (USD Million)
8.6.4. Parkinson's Disease (PD) Phase III
8.6.4.1. Parkinson's Disease (PD) Phase III Market Estimates and Forecasts, 2021-2033 (USD Million)
8.6.5. Parkinson's Disease (PD) Phase IV
8.6.5.1. Parkinson's Disease (PD) Phase IV Market Estimates and Forecasts, 2021-2033 (USD Million)
8.7. Epilepsy
8.7.1. Epilepsy Market Estimates and Forecasts, 2021-2033 (USD Million)
8.7.2. Epilepsy Phase I
8.7.2.1. Epilepsy Phase I Market Estimates and Forecasts, 2021-2033 (USD Million)
8.7.3. Epilepsy Phase II
8.7.3.1. Epilepsy Phase II Market Estimates and Forecasts, 2021-2033 (USD Million)
8.7.4. Epilepsy Phase III
8.7.4.1. Epilepsy Phase III Market Estimates and Forecasts, 2021-2033 (USD Million)
8.7.5. Epilepsy Phase IV
8.7.5.1. Epilepsy Phase IV Market Estimates and Forecasts, 2021-2033 (USD Million)
8.8. Stroke
8.8.1. Stroke Market Estimates and Forecasts, 2021-2033 (USD Million)
8.8.2. Stroke Phase I
8.8.2.1. Stroke Phase I Market Estimates and Forecasts, 2021-2033 (USD Million)
8.8.3. Stroke Phase II
8.8.3.1. Stroke Phase II Market Estimates and Forecasts, 2021-2033 (USD Million)
8.8.4. Stroke Phase III
8.8.4.1. Stroke Phase III Market Estimates and Forecasts, 2021-2033 (USD Million)
8.8.5. Stroke Phase IV
8.8.5.1. Stroke Phase IV Market Estimates and Forecasts, 2021-2033 (USD Million)
8.9. Traumatic Brain Injury (TBI)
8.9.1. Traumatic Brain Injury (TBI) Market Estimates and Forecasts, 2021-2033 (USD Million)
8.9.2. Traumatic Brain Injury (TBI) Phase I
8.9.2.1. Traumatic Brain Injury (TBI) Phase I Market Estimates and Forecasts, 2021-2033 (USD Million)
8.9.3. Traumatic Brain Injury (TBI) Phase II
8.9.3.1. Traumatic Brain Injury (TBI) Phase II Market Estimates and Forecasts, 2021-2033 (USD Million)
8.9.4. Traumatic Brain Injury (TBI) Phase III
8.9.4.1. Traumatic Brain Injury (TBI) Phase III Market Estimates and Forecasts, 2021-2033 (USD Million)
8.9.5. Traumatic Brain Injury (TBI) Phase IV
8.9.5.1. Traumatic Brain Injury (TBI) Phase IV Market Estimates and Forecasts, 2021-2033 (USD Million)
8.10. Amyotrophic Lateral Sclerosis (ALS)
8.10.1. Amyotrophic Lateral Sclerosis (ALS) Market Estimates and Forecasts, 2021-2033 (USD Million)
8.10.2. Amyotrophic Lateral Sclerosis (ALS) Phase I
8.10.2.1. Amyotrophic Lateral Sclerosis (ALS) Phase I Market Estimates and Forecasts, 2021-2033 (USD Million)
8.10.3. Amyotrophic Lateral Sclerosis (ALS) Phase II
8.10.3.1. Amyotrophic Lateral Sclerosis (ALS) Phase II Market Estimates and Forecasts, 2021-2033 (USD Million)
8.10.4. Amyotrophic Lateral Sclerosis (ALS) Phase III
8.10.4.1. Amyotrophic Lateral Sclerosis (ALS) Phase III Market Estimates and Forecasts, 2021-2033 (USD Million)
8.10.5. Amyotrophic Lateral Sclerosis (ALS) Phase IV
8.10.5.1. Amyotrophic Lateral Sclerosis (ALS) Phase IV Market Estimates and Forecasts, 2021-2033 (USD Million)
8.11. Huntington's Disease
8.11.1. Huntington's Disease Market Estimates and Forecasts, 2021-2033 (USD Million)
8.11.2. Huntington's Disease Phase I
8.11.2.1. Huntington's Disease Phase I Market Estimates and Forecasts, 2021-2033 (USD Million)
8.11.3. Huntington's Disease Phase II
8.11.3.1. Huntington's Disease Phase II Market Estimates and Forecasts, 2021-2033 (USD Million)
8.11.4. Huntington's Disease Phase III
8.11.4.1. Huntington's Disease Phase III Market Estimates and Forecasts, 2021-2033 (USD Million)
8.11.5. Huntington's Disease Phase IV
8.11.5.1. Huntington's Disease Phase IV Market Estimates and Forecasts, 2021-2033 (USD Million)
8.12. Muscle Regeneration
8.12.1. Muscle Regeneration Market Estimates and Forecasts, 2021-2033 (USD Million)
8.12.2. Muscle Regeneration Phase I
8.12.2.1. Muscle Regeneration Phase I Market Estimates and Forecasts, 2021-2033 (USD Million)
8.12.3. Muscle Regeneration Phase II
8.12.3.1. Muscle Regeneration Phase II Market Estimates and Forecasts, 2021-2033 (USD Million)
8.12.4. Muscle Regeneration Phase III
8.12.4.1. Muscle Regeneration Phase III Market Estimates and Forecasts, 2021-2033 (USD Million)
8.12.5. Muscle Regeneration Phase IV
8.12.5.1. Muscle Regeneration Phase IV Market Estimates and Forecasts, 2021-2033 (USD Million)
8.13. Others
8.13.1. Others Market Estimates and Forecasts, 2021-2033 (USD Million)
8.13.2. Others Phase I
8.13.2.1. Others Phase I Market Estimates and Forecasts, 2021-2033 (USD Million)
8.13.3. Others Phase II
8.13.3.1. Others Phase II Market Estimates and Forecasts, 2021-2033 (USD Million)
8.13.4. Others Phase III
8.13.4.1. Others Phase III Market Estimates and Forecasts, 2021-2033 (USD Million)
8.13.5. Others Phase IV
8.13.5.1. Others Phase IV Market Estimates and Forecasts, 2021-2033 (USD Million)
Chapter 9. Middle East Neurology Clinical Trials Market: Value Chain Estimates & Trend Analysis
9.1. Middle East Neurology Clinical Trials Market, by Value Chain: Segment Dashboard
9.2. Middle East Neurology Clinical Trials Market, by Value Chain: Movement Analysis
9.3. Middle East Neurology Clinical Trials Market Estimates & Forecasts, by Value Chain, 2021-2033 (USD Million)
9.4. In-house
9.4.1. In-house Market Estimates and Forecasts, 2021-2033 (USD Million)
9.5. CROs
9.5.1. CROs Market Estimates and Forecasts, 2021-2033 (USD Million)
9.6. Investigator Sites/Clinical Sites
9.6.1. Investigator Sites/Clinical Sites Market Estimates and Forecasts, 2021-2033 (USD Million)
Chapter 10. Middle East Neurology Clinical Trials Market: Regional Estimates & Trend Analysis
10.1. Regional Market Dashboard
10.2. Regional Market Share Analysis, 2024 & 2033
10.3. Middle East
10.3.1. Middle East Market Estimates and Forecasts, 2021-2033 (USD Million)
10.3.2. Saudi Arabia
10.3.2.1. Key Country Dynamics
10.3.2.2. Competitive Scenario
10.3.2.3. Regulatory Framework
10.3.2.4. Saudi Arabia Market Estimates and Forecasts, 2021-2033 (USD Million)
10.3.3. UAE
10.3.3.1. Key Country Dynamics
10.3.3.2. Competitive Scenario
10.3.3.3. Regulatory Framework
10.3.3.4. UAE Market Estimates and Forecasts, 2021-2033 (USD Million)
10.3.4. Kuwait
10.3.4.1. Key Country Dynamics
10.3.4.2. Competitive Scenario
10.3.4.3. Regulatory Framework
10.3.4.4. Kuwait Market Estimates and Forecasts, 2021-2033 (USD Million)
10.3.5. Oman
10.3.5.1. Key Country Dynamics
10.3.5.2. Competitive Scenario
10.3.5.3. Regulatory Framework
10.3.5.4. Oman Market Estimates and Forecasts, 2021-2033 (USD Million)
10.3.6. Qatar
10.3.6.1. Key Country Dynamics
10.3.6.2. Competitive Scenario
10.3.6.3. Regulatory Framework
10.3.6.4. Qatar Market Estimates and Forecasts, 2021-2033 (USD Million)
Chapter 11. Competitive Landscape
11.1. Participant Categorization
11.2. Market Position Analysis, 2024 (Heat Map Analysis)
11.3. Company Profiles
11.3.1. Syneos Health
11.3.1.1. Company Overview
11.3.1.2. Financial Performance
11.3.1.3. Service Benchmarking
11.3.1.4. Strategic Initiatives
11.3.2. Icon Plc
11.3.2.1. Company Overview
11.3.2.2. Financial Performance
11.3.2.3. Service Benchmarking
11.3.2.4. Strategic Initiatives
11.3.3. Pfizer
11.3.3.1. Company Overview
11.3.3.2. Financial Performance
11.3.3.3. Service Benchmarking
11.3.3.4. Strategic Initiatives
11.3.4. Novartis
11.3.4.1. Company Overview
11.3.4.2. Financial Performance
11.3.4.3. Service Benchmarking
11.3.4.4. Strategic Initiatives
11.3.5. Roche / Genentech
11.3.5.1. Company Overview
11.3.5.2. Financial Performance
11.3.5.3. Service Benchmarking
11.3.5.4. Strategic Initiatives
11.3.6. Sanofi
11.3.6.1. Company Overview
11.3.6.2. Financial Performance
11.3.6.3. Service Benchmarking
11.3.6.4. Strategic Initiatives
11.3.7. Teva
11.3.7.1. Company Overview
11.3.7.2. Financial Performance
11.3.7.3. Service Benchmarking
11.3.7.4. Strategic Initiatives
11.3.8. Janssen (Johnson & Johnson)
11.3.8.1. Company Overview
11.3.8.2. Financial Performance
11.3.8.3. Service Benchmarking
11.3.8.4. Strategic Initiatives
11.3.9. Biogen
11.3.9.1. Company Overview
11.3.9.2. Financial Performance
11.3.9.3. Service Benchmarking
11.3.9.4. Strategic Initiatives
11.3.10. AstraZeneca
11.3.10.1. Company Overview
11.3.10.2. Financial Performance
11.3.10.3. Service Benchmarking
11.3.10.4. Strategic Initiatives
11.3.11. IQVIA
11.3.11.1. Company Overview
11.3.11.2. Financial Performance
11.3.11.3. Service Benchmarking
11.3.11.4. Strategic Initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Middle East Neurology Clinical Trials Market Estimates and Forecasts, by Phase, 2021-2033 (USD Million)
Table 4 Middle East Neurology Clinical Trials Market Estimates and Forecasts, by Study Design, 2021-2033 (USD Million)
Table 5 Middle East Neurology Clinical Trials Market Estimates and Forecasts, by Indication, 2021-2033 (USD Million)
Table 6 Middle East Neurology Clinical Trials Market Estimates and Forecasts, by Indication by Study Design, 2021-2033 (USD Million)
Table 7 Middle East Neurology Clinical Trials Market Estimates and Forecasts, by Indication by Phase, 2021-2033 (USD Million)
Table 8 Middle East Neurology Clinical Trials Market Estimates and Forecasts, by Value Chain, 2021-2033 (USD Million)
Table 9 Saudi Arabia Neurology Clinical Trials Market Estimates and Forecasts, by Phase, 2021-2033 (USD Million)
Table 10 Saudi Arabia Neurology Clinical Trials Market Estimates and Forecasts, by Study Design, 2021-2033 (USD Million)
Table 11 Saudi Arabia Neurology Clinical Trials Market Estimates and Forecasts, by Indication, 2021-2033 (USD Million)
Table 12 Saudi Arabia Neurology Clinical Trials Market Estimates and Forecasts, by Indication by Study Design, 2021-2033 (USD Million)
Table 13 Saudi Arabia Neurology Clinical Trials Market Estimates and Forecasts, by Indication by Phase, 2021-2033 (USD Million)
Table 14 Saudi Arabia Neurology Clinical Trials Market Estimates and Forecasts, by Value Chain, 2021-2033 (USD Million)
Table 15 UAE Neurology Clinical Trials Market Estimates and Forecasts, by Phase, 2021-2033 (USD Million)
Table 16 UAE Neurology Clinical Trials Market Estimates and Forecasts, by Study Design, 2021-2033 (USD Million)
Table 17 UAE Neurology Clinical Trials Market Estimates and Forecasts, by Indication, 2021-2033 (USD Million)
Table 18 UAE Neurology Clinical Trials Market Estimates and Forecasts, by Indication by Study Design, 2021-2033 (USD Million)
Table 19 UAE Neurology Clinical Trials Market Estimates and Forecasts, by Indication by Phase, 2021-2033 (USD Million)
Table 20 UAE Neurology Clinical Trials Market Estimates and Forecasts, by Value Chain, 2021-2033 (USD Million)
Table 21 Kuwait Neurology Clinical Trials Market Estimates and Forecasts, by Phase, 2021-2033 (USD Million)
Table 22 Kuwait Neurology Clinical Trials Market Estimates and Forecasts, by Study Design, 2021-2033 (USD Million)
Table 23 Kuwait Neurology Clinical Trials Market Estimates and Forecasts, by Indication, 2021-2033 (USD Million)
Table 24 Kuwait Neurology Clinical Trials Market Estimates and Forecasts, by Indication by Study Design, 2021-2033 (USD Million)
Table 25 Kuwait Neurology Clinical Trials Market Estimates and Forecasts, by Indication by Phase, 2021-2033 (USD Million)
Table 26 Kuwait Neurology Clinical Trials Market Estimates and Forecasts, by Value Chain, 2021-2033 (USD Million)
Table 27 Oman Neurology Clinical Trials Market Estimates and Forecasts, by Phase, 2021-2033 (USD Million)
Table 28 Oman Neurology Clinical Trials Market Estimates and Forecasts, by Study Design, 2021-2033 (USD Million)
Table 29 Oman Neurology Clinical Trials Market Estimates and Forecasts, by Indication, 2021-2033 (USD Million)
Table 30 Oman Neurology Clinical Trials Market Estimates and Forecasts, by Indication by Study Design, 2021-2033 (USD Million)
Table 31 Oman Neurology Clinical Trials Market Estimates and Forecasts, by Indication by Phase, 2021-2033 (USD Million)
Table 32 Oman Neurology Clinical Trials Market Estimates and Forecasts, by Value Chain, 2021-2033 (USD Million)
Table 33 Qatar Neurology Clinical Trials Market Estimates and Forecasts, by Phase, 2021-2033 (USD Million)
Table 34 Qatar Neurology Clinical Trials Market Estimates and Forecasts, by Study Design, 2021-2033 (USD Million)
Table 35 Qatar Neurology Clinical Trials Market Estimates and Forecasts, by Indication, 2021-2033 (USD Million)
Table 36 Qatar Neurology Clinical Trials Market Estimates and Forecasts, by Indication by Study Design, 2021-2033 (USD Million)
Table 37 Qatar Neurology Clinical Trials Market Estimates and Forecasts, by Indication by Phase, 2021-2033 (USD Million)
Table 38 Qatar Neurology Clinical Trials Market Estimates and Forecasts, by Value Chain, 2021-2033 (USD Million)
List of Figures
Figure 1 Market research process
Figure 2 Information procurement
Figure 3 Primary research pattern
Figure 4 Market research approaches
Figure 5 Market formulation & validation
Figure 6 Commodity flow analysis
Figure 7 Value-chain-based sizing & forecasting
Figure 8 QFD model sizing & forecasting
Figure 9 Bottom-up approach
Figure 10 Market snapshot
Figure 11 Segment snapshot 1
Figure 12 Segment snapshot 2
Figure 13 Competitive landscape snapshot
Figure 14 Parent market outlook, 2024 (USD Billion)
Figure 15 Ancillary market outlook, 2024 (USD Billion)
Figure 16 Middle East Neurology Clinical Trials Market Dynamics
Figure 17 Porter’s five forces analysis
Figure 18 PESTEL analysis
Figure 19 Middle East Neurology Clinical Trials Market: Phase outlook and key takeaways
Figure 20 Middle East Neurology Clinical Trials Market: Phase movement analysis
Figure 21 Phase I Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 22 Phase II Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 23 Phase III Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 24 Phase IV Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 25 Middle East Neurology Clinical Trials Market: Study design outlook and key takeaways
Figure 26 Middle East Neurology Clinical Trials Market: Study design movement analysis
Figure 27 Interventional Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 28 Observational Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 29 Expanded Access Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 30 Middle East Neurology Clinical Trials Market: Indication outlook and key takeaways
Figure 31 Middle East Neurology Clinical Trials Market: Indication movement analysis
Figure 32 Alzheimer’s Disease Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 33 Depression (MDD) Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 34 Parkinson's Disease (PD) Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 35 Epilepsy Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 36 Stroke Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 37 Traumatic Brain Injury (TBI) Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 38 Amyotrophic Lateral Sclerosis (ALS) Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 39 Huntington's Disease Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 40 Muscle Regeneration Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 41 Others Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 42 Middle East Neurology Clinical Trials Market: Indication by Study Design outlook and key takeaways
Figure 43 Middle East Neurology Clinical Trials Market: Indication by Study Design movement analysis
Figure 44 Alzheimer’s Disease Interventional Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 45 Alzheimer’s Disease Observational Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 46 Alzheimer’s Disease Expanded Access Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 47 Depression (MDD) Interventional Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 48 Depression (MDD) Observational Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 49 Depression (MDD) Expanded Access Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 50 Parkinson's Disease (PD) Interventional Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 51 Parkinson's Disease (PD) Observational Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 52 Parkinson's Disease (PD) Expanded Access Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 53 Epilepsy Interventional Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 54 Epilepsy Observational Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 55 Epilepsy Expanded Access Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 56 Stroke Interventional Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 57 Stroke Observational Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 58 Stroke Expanded Access Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 59 Traumatic Brain Injury (TBI) Interventional Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 60 Traumatic Brain Injury (TBI) Observational Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 61 Traumatic Brain Injury (TBI) Expanded Access Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 62 Amyotrophic Lateral Sclerosis (ALS) Interventional Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 63 Amyotrophic Lateral Sclerosis (ALS) Observational Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 64 Amyotrophic Lateral Sclerosis (ALS) Expanded Access Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 65 Huntington's Disease Interventional Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 66 Huntington's Disease Observational Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 67 Huntington's Disease Expanded Access Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 68 Muscle Regeneration Interventional Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 69 Muscle Regeneration Observational Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 70 Muscle Regeneration Expanded Access Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 71 Others Interventional Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 72 Others Observational Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 73 Others Expanded Access Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 74 Middle East Neurology Clinical Trials Market: Value Chain Design outlook and key takeaways
Figure 75 Middle East Neurology Clinical Trials Market: Value Chain movement analysis
Figure 76 In-house Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 77 CROs Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 78 Investigator Sites/Clinical Sites Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 79 Regional Marketplace: Key Takeaways
Figure 80 Middle East Neurology Clinical Trials Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 81 Key country dynamics
Figure 82 Saudi Arabia Neurology Clinical Trials Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 83 Key country dynamics
Figure 84 UAE Neurology Clinical Trials Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 85 Key country dynamics
Figure 86 Kuwait Neurology Clinical Trials Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 87 Key country dynamics
Figure 88 Oman Neurology Clinical Trials Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 89 Key country dynamics
Figure 90 Qatar Neurology Clinical Trials Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 91 Key company categorization
Figure 92 Service heat map analysis
Figure 93 Strategic framework

Companies Mentioned

The leading players profiled in this Middle East Neurology Clinical Trials market report include:
  • Syneos Health
  • Icon Plc
  • Pfizer
  • Novartis
  • Roche / Genentech
  • Sanofi
  • Teva
  • Janssen (Johnson & Johnson)
  • Biogen
  • AstraZeneca
  • IQVIA

Table Information

Report AttributeDetails
No. of Pages120
PublishedSeptember 2025
Forecast Period2025 - 2033
Estimated Market Value ( USD ) in 2025 $ 45.19 Million
Forecasted Market Value ( USD ) by 2033 $ 68.78 Million
Compound Annual Growth Rate5.3%
Regions CoveredMiddle East
No. of Companies Mentioned12

Related Topics

Related Reports

U.S. Neurology Clinical Trials Market Size, Share & Trends Analysis Report by Phase (Phase I, Phase II, Phase III, Phase IV), by Study Design, by Indication, by Indication by Study Design, by Indication by Phase, by Value Chain, and Segment Forecasts, 2025-2033 - Product Image

U.S. Neurology Clinical Trials Market Size, Share & Trends Analysis Report by Phase (Phase I, Phase II, Phase III, Phase IV), by Study Design, by Indication, by Indication by Study Design, by Indication by Phase, by Value Chain, and Segment Forecasts, 2025-2033

  • Report
  • 120 Pages
  • United States
From
Neurology Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design, By Indication, By Indication by Study Design, By Indication by Phase, By Value Chain, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Neurology Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design, By Indication, By Indication by Study Design, By Indication by Phase, By Value Chain, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 120 Pages
  • Global
From
North America Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design, By Indication, By Indication by Study Design, By Service, By Sponsor, By Country, And Segment Forecasts, 2025 - 2033 - Product Image

North America Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design, By Indication, By Indication by Study Design, By Service, By Sponsor, By Country, And Segment Forecasts, 2025 - 2033

  • Report
  • 150 Pages
  • North America
From
Middle East Clinical Trials Market Size, Share & Trends Analysis Report by Phase (Phase I, Phase II, Phase III, Phase IV), Study Design, Indication, Indication by Study Design, Service, Sponsor, and Country with Growth Forecasts, 2025-2033 - Product Image

Middle East Clinical Trials Market Size, Share & Trends Analysis Report by Phase (Phase I, Phase II, Phase III, Phase IV), Study Design, Indication, Indication by Study Design, Service, Sponsor, and Country with Growth Forecasts, 2025-2033

  • Report
  • 180 Pages
  • Middle East
From
Asia Pacific Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Indication, By Study Design, By Service, By Indication by Study Design, By Sponsor, By Country, And Segment Forecasts, 2025 - 2033 - Product Image

Asia Pacific Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Indication, By Study Design, By Service, By Indication by Study Design, By Sponsor, By Country, And Segment Forecasts, 2025 - 2033

  • Report
  • 80 Pages
  • Asia Pacific
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.